Fig. 2From: Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trialReductions from baseline in renal angiomyolipoma volume in each study visit. The study ended as per protocol 1 year after first patient enrolment, which explains the reduced number of patients available at month 12Back to article page